Advertisement

Author: Staff

Advertisement

Seattle-based pharmaceutical company Omeros announced positive results from its final Phase 3 clinical trial of OMS302, a drug added to irrigation solutions after cataract or lens replacement surgery.

Reimbursement cuts and changing delivery models were among the topics discussed by panelists at the joint meeting for the American Academy of Ophthalmology and Asia-Pacific Academy of Ophthalmology in Chicago, according to a report by Ocular Surgery News.

Neighborhood Health Plan and Partners HealthCare gave out $4.25 million in grants for its Partnership for Community Health program to fund health information technology, according to Government Health IT.

Advertisement